Diffusion Pharmaceuticals (NASDAQ:DFFN) has announced its financial results for the year ended December 31, 2018. As quoted in the press release: 2018 was marked by significant developments related to the Company’s lead drug candidate, trans sodium crocetinate (TSC), for the treatment of stroke and cancer. During the third quarter Diffusion received approval from the U.S. … Continued
The post Diffusion Pharmaceuticals Reports 2018 Financial Results appeared first on Investing News Network.
Original Article: Diffusion Pharmaceuticals Reports 2018 Financial Results